EBC is a network of key players in the “Brain Area”, with a membership encompassing scientific societies, patient organisations, professional societies and industry partners.
8 12-2022

Registration now open for the launch event of the RETHINKING Alzheimer’s disease White Paper

2023-01-10T12:03:16+00:0008-12-2022|News|

Registration is now open for the launch event of the RETHINKING Alzheimer's disease White Paper, taking place virtually on 24 January 2023 at 12:30 – 14:00. The European Brain Council (EBC), in collaboration with the European Federation of Pharmaceutical Industries and Associations (EFPIA), will present its White Paper “RETHINKING Alzheimer’s disease: Detection and diagnosis“. This paper [...]

24 11-2022

Save the date for the launch event of the RETHINKING Alzheimer’s disease White Paper!

2023-01-10T13:12:36+00:0024-11-2022|News|

The launch event of the RETHINKING Alzheimer's disease White Paper, calling for change in Alzheimer's care, will take place virtually on 24 January 2023 at 12:30 - 14:00. About Alzheimer's disease Alzheimer’s disease (AD) is a neurodegenerative disease that progresses in stages, beginning with a long silent phase before symptoms occur. It is the underlying cause [...]

10 11-2022

Launch event of the RETHINKING Alzheimer’s disease White Paper

2023-01-11T08:46:20+00:0010-11-2022|

The launch event of the RETHINKING Alzheimer’s disease White Paper, calling for change in Alzheimer’s care, will take place virtually on 24 January 2023 at 12:30 – 14:00. The European Brain Council (EBC), in collaboration with the European Federation of Pharmaceutical Industries and Associations (EFPIA), will present its White Paper “RETHINKING Alzheimer’s disease: Detection and diagnosis“. This paper is [...]

26 10-2022

Alzheimer Europe Conference: Symposium on rethinking the early detection and diagnosis of Alzheimer’s disease

2023-02-06T12:34:26+00:0026-10-2022|News|

Alzheimer’s disease (AD) is a major unmet medical need that requires innovation to be aligned with public health needs. It represents between 60% and 70% of the dementia cases. It is still diagnosed too late when the symptoms become evident as the disease progresses.  AD is now portrayed as continuum consisting of 3 stages: [...]

16 09-2022

Rethinking the early detection and diagnosis of Alzheimer’s disease | Alzheimer Europe Conference

2023-02-24T10:57:04+00:0016-09-2022|

Alzheimer’s disease (AD) is a major unmet medical need that requires innovation to be aligned with public health and health systems‘ needs. AD represents between 60 and%70% of the dementia cases. It is still diagnosed too late, when the symptoms become more evident as the disease progresses. AD is now portrayed as a continuum [...]

24 05-2022

RETHINKING Alzheimer’s disease project, calling for change in Alzheimer’s care, kicks off!

2022-05-24T07:55:53+00:0024-05-2022|News|

Through RETHINKING Alzheimer’s disease (AD), the European Brain Council (EBC) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) are joining forces with the ambition of improving Alzheimer’s disease care pathway and the lives of people living with it. Officially launched on 29 April 2022, the project kicked off its operational activities with [...]

Go to Top